Published on
May 6, 2025
Rewrite The APPLE’s core question—upfront osimertinib versus the sequential approach for EGFR mutated non-small cell ...
Activating epidermal growth factor receptor (EGFR) mutations in lung cancer are reported in approximately 50% of Asian and 15% of Caucasian patients diagnosed with non-small cell lung cancer (NSCLC) (1). Tyrosine kinase inhibitors (TKIs) have become the …
Source:
Bioengineer.org
-
Pending
